Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

N. Beije, J. Kraan, W. Taal, B. van der Holt, H.M. Oosterkamp, A.M. Walenkamp, L. Beerepoot, M. Hanse, M.E. van Linde, A. Otten, R.M. Vernhout, F.Y.F. de Vos, J.W. Gratama, S. Sleijfer, M.J. van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)226-231
JournalBritish journal of cancer
Issue number2
Publication statusPublished - 2015

Cite this